



Endothelial function after ST-elevation myocardial infarction in patients with high levels of high-sensitivity CRP and Lp-PLA₂: A substudy of the RESPONSE randomized trial^{☆☆}



Jasveen J. Kandhai-Ragunath^a, Bjorn de Wagenaar^b, Cees Doelman^c, Jan van Es^a, Harald T. Jørstad^d, Ron J.G. Peters^d, Carine J.M. Doggen^e, Clemens von Birgelen^{a,e,*}

^a Department of Cardiology, Thoraxcentrum Twente, MST, Enschede, Netherlands

^b MESA, Institute for Nanotechnology, University of Twente, Enschede, Netherlands

^c Medlon Laboratory Diagnostics, Medisch Spectrum Twente, Enschede, Netherlands

^d Department of Cardiology, Academisch Medisch Centrum, Amsterdam, Netherlands

^e Health Technology and Services Research, MIRA – Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, Netherlands

ARTICLE INFO

Article history:

Received 29 August 2016

Received in revised form 23 December 2016

Accepted 28 December 2016

Keywords:

Endothelial function (dysfunction)

ST-elevation myocardial infarction (STEMI)

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂)

High-sensitive C-reactive protein (hs-CRP)

ABSTRACT

Background: The combination of high levels of high-sensitive C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase-A₂ (Lp-PLA₂) was recently shown to correlate with increased cardiovascular risk. Endothelial dysfunction is also known to be a risk factor for cardiovascular events.

Aim: To test among patients with previous ST-elevation myocardial infarction (STEMI) the hypothesis that high levels of both hs-CRP and Lp-PLA₂ may be associated with impaired endothelium-dependent vasodilatation.

Methods: In this substudy of the RESPONSE randomized trial, we used reactive hyperemia peripheral artery tonometry (RH-PAT) 4 to 6 weeks after STEMI and primary percutaneous coronary intervention (PPCI) to non-invasively assess endothelial function (RH-PAT index <1.67 identified endothelial dysfunction). Reliable measurements of RH-PAT, hs-CRP, and Lp-PLA₂ were obtained in 68 patients, who were classified as high-risk if levels of both hs-CRP and Lp-PLA₂ were in the upper tertile (≥ 3.84 mg/L and >239 μ g/L, respectively).

Results: Patients were 57.4 ± 9.7 years and 53 (77.9%) were men. 11 (16%) patients were classified as high-risk and 57 (84%) as low-to-intermediate-risk. The RH-PAT index was 1.68 ± 0.22 in high-risk and 1.95 ± 0.63 in low-to-intermediate-risk patients ($p = 0.17$). Endothelial dysfunction was present in 8 (72.7%) high-risk and 26 (45.6%) low-to-intermediate-risk patients ($p = 0.09$). Framingham risk score, NT-proBNP and fibrinogen levels were higher in high-risk patients ($p \leq 0.03$).

Conclusion: In this population of patients with recent STEMI and PPCI, we observed between patients with high hs-CRP and Lp-PLA levels and all other patients no more than numerical differences in endothelial function that did not reach a statistical significance. Nevertheless, further research in larger study populations may be warranted.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Abbreviations: hs-CRP, high-sensitive C-reactive protein; Lp-PLA₂, lipoprotein-associated phospholipase A₂; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; RH-PAT, reactive hyperemia peripheral artery tonometry; STEMI, ST-elevation myocardial infarction.

^{*} Potential conflicts of interest: The research department of Thoraxcentrum Twente has received research grants funded by AstraZeneca, and CvB has received lecture fees from AstraZeneca. RJGP is a consultant to AstraZeneca. All other authors declare that they have no conflict of interest.

^{☆☆} Funding: This investigator-initiated, non-funded observational study was performed in a single-center STEMI patient population that was also enrolled in the RESPONSE multi-center trial, funded by AstraZeneca. There is no financial or other conflict of interest other than stated; there were no other sponsors than indicated.

^{*} Corresponding author at: Thoraxcentrum Twente, Department of Cardiology, Haaksbergerstraat 55, 7513ER Enschede, Netherlands. Tel.: +31 53 487 2105; fax: +31 53 487 2107.

E-mail address: c.vonbirgelen@mst.nl (C. von Birgelen).

1. Introduction

While common cardiovascular risk factors at best provide a reasonable prediction of cardiovascular events [1], the addition of biomarkers of systemic inflammation, such as high-sensitive C-reactive protein (hs-CRP), can improve risk prediction [2]. A recently published study showed that an aggregate risk score including hs-CRP greatly enhanced the risk prediction of death and myocardial infarction in patients with suspected or known coronary artery disease [4]. In addition, lipoprotein-associated phospholipase A₂ (Lp-PLA₂), a specific marker for vascular inflammation, was found to predict future cardiovascular events independently of hs-CRP [5–7], suggesting an additive role for risk prediction. This is supported by the fact that in a population-based study, the combination of elevated levels of hs-CRP and Lp-PLA₂ correlated with increased cardiovascular risk [8].

Patients who survive an ST-elevation myocardial infarction (STEMI) are at high risk of future recurrent cardiovascular events [9]. Within this patient population, the combination of elevated levels of hs-CRP and Lp-PLA₂ might be able to identify subjects with a particularly high risk. As endothelial dysfunction (i.e. impaired endothelium-dependent arterial vasodilatation) is known to be an independent risk factor of future cardiovascular events [10,11], we tested in a local substudy of the RESPONSE (Randomised Evaluation of Secondary Prevention by Outpatient Nurse Specialists) trial [14] the hypothesis that elevated levels of both hs-CRP and Lp-PLA₂ may be associated with reduced endothelial function in patients with recent STEMI.

2. Methods

2.1. Study population and study design

This prospective cohort study was performed in STEMI patients of the RESPONSE trial [12], who underwent treatment by PPCI for acute STEMI (≤ 12 h after symptom onset) and non-invasive assessment of endothelial function with the RH-PAT method after 4 to 6 weeks at Thoraxcentrum Twente in Enschede. PPCIs were performed between October 2007 and December 2008. Of a total of 75 RESPONSE trial participants at Thoraxcentrum Twente, who were treated for STEMI and underwent RH-PAT measurements, 71 had analyzable RH-PAT registrations and 68 patients had laboratory measurements of hs-CRP and LpPLA₂. This resulted in a study population of 68 patients.

Details of the randomized RESPONSE trial have previously been reported [12]. In brief, patients had to be 18 to 80 years, without surgery or additional PCI being planned within 8 weeks from PPCI, without congestive heart failure New York Heart Association (NYHA) class III or IV, and with a life expectancy of at least 2 years.

As inflammation and repair processes of the infarcted myocardium might have disturbed endothelial function measurements during the first weeks after the STEMI and endothelial dysfunction had not been fully recovered under medication, endothelial function was assessed 4 to 6 weeks after the PPCI [13–15]. All patients were seen in the outpatient clinic and the research department of Thoraxcentrum Twente, where non-invasive assessment of the endothelial function was performed according to strict rules in a dedicated laboratory [16].

All patients provided written informed consent for both participation in the RESPONSE multicenter trial and the present single-center substudy. Trial and substudy complied with the Declaration of Helsinki for investigation in human beings and were approved by accredited Medical Ethical Committees in Amsterdam and Twente, the Netherlands.

2.2. Patient characteristics and follow-up

The following information was collected through interviews during visits in our outpatient clinic 4 to 6 weeks after STEMI: age; sex; body mass index (kg/m^2); arterial hypertension (blood pressure $>140/90$ mmHg or treatment with anti-hypertensive medication); history of smoking (previous or current smoker); history of previous myocardial infarction or percutaneous coronary intervention (PCI); presence of diabetes mellitus (patient history and/or treatment with insulin or oral anti-glycemic agents); and history of hyperlipidemia or treatment with lipid-lowering drugs. The Framingham Risk Score (10-year risk prediction for fatal and non-fatal coronary heart disease) was determined to sketch a patient risk profile.

2.3. Laboratory assessment of the biochemical markers

Venous blood samples were drawn after a minimum of 8 h of fasting. The laboratory markers total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, hemoglobin A1c, creatinine, fibrinogen, apolipoprotein A1 & B100, troponin I and N-terminal pro-B-type natriuretic peptide

(NT-proBNP) were assessed according to manufacturer instructions. After centrifugation, plasma and serum aliquots were stored at -80 °C. A commercially available Lp-PLA₂ enzyme-linked immunosorbent assay kit (third generation PLACTM Test; diaDexus Inc., South San Francisco, CA) was used to determine the lipoprotein-associated phospholipase A₂ mass. The inter-assay precision was determined by measuring two controls of known concentration (low and high) in 10 separate assays. The coefficient of variation on all 10 plates was 7% and 6%, respectively. The hs-CRP concentrations were determined by nephelometry using a BN ProSpec® system (Siemens). The detection limit was 0.23 mg/L and the mean inter-assay coefficient of variation was 2.8%.

The thresholds of the hs-CRP tertiles were determined at 1.03 mg/L and 3.84 mg/L; the thresholds of the Lp-PLA₂ tertiles were 190 $\mu\text{g}/\text{L}$ and 239 $\mu\text{g}/\text{L}$ comparable to AHA/CDC guidelines [17] and ARIC study [8].

2.4. Assessment of endothelial function

Endothelial function was evaluated with the RH-PAT method. The finger pulse wave amplitude was assessed with the EndoPAT-2000 sensing device and finger plethysmographic probes (Itamar Medical, Caesarea, Israel), both at baseline and during ischemia-induced hyperemia. All measurements were performed in the early morning in a dedicated laboratory after fasting for at least 8 h. Patients also had to refrain from caffeine consumption, smoking, and vasoactive medications. At least 15 min prior to testing, blood pressure was measured and a blood sample was drawn in the control arm. Before any measurement, patients had an acclimatization period of 20 min in a quiet room, lying in a hospital bed at an ambient temperature of 21 to 23 °C.

The RH-PAT method has previously been reported in detail [18–20]. In brief, measurements were performed by the use of probes on index fingers of both the study and control arm. Baseline measurements were recorded for 5 min prior to inducing ischemia by inflating a blood pressure cuff on the upper arm of the study arm for 5 min to supra-systolic pressures. This led to NO release from functional endothelium and thus vasodilatation, which was recorded by the sensors in the finger cuff through beat-to-beat finger pulse wave analysis [19,21]. Following the release of the blood pressure cuff, the ratio of the pulse amplitude of the hyperemic finger and the baseline amplitude was calculated. Subsequently, that ratio was divided by the corresponding ratio, obtained in the control arm, to calculate the RH-PAT index (high values indicate good endothelial function) [19,21]. Hamburg et al. demonstrated that the maximum hyperemic response can be expected 90 to 120 s after cuff deflation [20]. Therefore, in the present study, the reactive RH-PAT index was calculated as the ratio of the mean hyperemic pulse wave analysis over a period of 30 s, beginning at 90 s after cuff deflation, divided by the baseline pulse wave analysis (mean baseline measurements for 3.5 min), and normalized to the concurrent measurements of the control arm. Based on previously reported data, endothelial function was divided into two groups: endothelial dysfunction (RH-PAT <1.67) and normal endothelial function (RH-PAT ≥ 1.67) [21].

2.5. Statistical analysis

Data are presented as frequencies (%) or mean \pm standard deviation (SD). We used the Fisher's exact chi-square test for categorical variables and the T-test for continuous variables to compare patients with high risk versus patients with low-to-intermediate risk. A *p*-value <0.05 was considered statistically significant. Analyses were performed with SPSS (version 21.0).

3. Results

3.1. Characteristics of the study population

Demographics and clinical characteristics of the 68 patients of the study population are presented in Table 1. Overall, patients were 57.4 ± 9.7 years and predominantly men ($n = 53$, 77.9%).

3.2. Biochemical marker-based classification of risk

The thresholds of the hs-CRP tertiles were determined at 1.03 mg/L and 3.84 mg/L; the thresholds of the Lp-PLA₂ tertiles were 190 µg/L and 239 µg/L. The thresholds of the upper tertiles of Lp-PLA₂ and hs-CRP were used to classify patients into a high-risk group versus a low-to-intermediate-risk group. A total of 11 patients with Lp-PLA₂ and hs-CRP levels in the highest tertile were classified as high-risk, while the remaining 57 patients were classified as low-to-intermediate-risk. Medical therapy and most cardiovascular risk factors did not differ between high-risk and low-to-intermediate-risk patients (Table 2). When the patients were further subdivided in three risk groups, high-, intermediate- and low-risk group, no differences were found either. Although the Framingham Risk Score is not designed to be used in this subset of patients, it does, however, provide an insight in the cardiovascular risk. The risk score is as predicted higher in the biomarker high-risk group (14.2 ± 6.8 vs. 10.0 ± 5.4 , $p < 0.05$). Among the laboratory parameters (Table 2), the following showed higher levels in the high-risk patient group: fibrinogen (4.84 ± 0.87 g/L vs. 3.71 ± 0.75 g/L, $p < 0.001$) and NT-proBNP (93.83 ± 106.54 vs. 44.29 ± 48.44 pmol/L, $p < 0.05$). The separation in three biomarker-based risk groups did not made any difference.

3.3. Endothelial function and biochemical marker-based classification of risk

The RH-PAT index was non-significantly lower (i.e. lower endothelial function) in high-risk patients than in low-to-intermediate-risk patients (1.68 ± 0.22 vs. 1.95 ± 0.63 , $p = 0.17$) (Fig. 1). Of the high-risk group, 8 patients (72.7%) had endothelial dysfunction (i.e. RH-PAT < 1.67), whereas in the low-to-intermediate-risk group, endothelial dysfunction was observed in 26 (45.6%) patients ($p = 0.09$).

4. Discussion

Traditional risk factor-based identification of patients who are at an increased risk of cardiovascular events is of limited value [1]. In several studies, the systemic inflammation marker hs-CRP was shown to predict the risk of secondary adverse cardiovascular events in patients with unstable angina or acute myocardial infarction [3]. Moreover, in the PROVE IT-TIMI 22 trial, the vascular inflammatory marker Lp-PLA₂, measured 30 days after an acute event, predicted recurrent cardiovascular events [6]. The combined prognostic value of hs-CRP and Lp-PLA₂, which has previously been studied in a population-based trial [7,8], may be of value for secondary risk prediction in patients with a recently acute coronary event. As patients who survive a STEMI are at particularly high risk of subsequent adverse events and death [22], improved

prediction of individuals with the highest event risk would be particularly valuable among such patients.

Endothelial dysfunction is considered to be a legitimate surrogate marker of cardiovascular risk [23–25,30]. In addition, the RH-PAT method previously found a lower endothelial function in patients with versus without coronary artery disease, suggesting a relation between RH-PAT index and cardiovascular risk [26]. Therefore, in the present study, we assessed whether patients with recent STEMI and elevated levels of both hs-CRP and Lp-PLA₂ had a worse endothelial function, as determined by RH-PAT. The STEMI and the primary PCI induce systemic endothelial dysfunction and an inflammatory response, which peaks at 1 to 2 days after the acute event before it gradually decreases, and the process of “myocardial repair” may be greatly finished after 3 weeks [27,28]. In order to avoid disturbance of endothelial function and inflammatory marker measurements, we performed it after 4 to 6 weeks from STEMI.

Data from other studies on the relation between biomarkers and endothelial function following recent STEMI are scarce. However, in a study in 42 men with stable coronary artery disease and well controlled low-density lipoprotein cholesterol serum levels, hs-CRP and Lp-PLA₂ were found to be useful to distinguish high-risk patients from patients with moderate or low event risk [29]. This supports the findings of the large Atherosclerosis Risk in Communities (ARIC) study, which showed that the levels of Lp-PLA₂ and CRP may be complementary beyond traditional risk factors in identifying middle-aged men and women at increased risk for ischemic stroke or incident coronary heart disease [7–8].

Our current study showed a non-significantly ($p = 0.09$) lower endothelial function in STEMI patients who were classified as high-risk, based on the biomarker assessment. Based on the data of the present substudy of the RESPONSE trial, we cannot exclude that the rate of subjects with endothelial dysfunction might be higher among patients with elevation of both biomarkers of inflammation, but the absence of statistical significance prevents any definite conclusion. Larger studies are warranted to further investigate this issue and to assess whether the use of additional biomarkers or patient characteristics may result in clinically useful secondary risk prediction models for patients with a recent STEMI. Nevertheless, one should bear in mind that all patients with a recent STEMI have an increased risk of additional cardiovascular events and that the identification of patients with the highest risk is most challenging among such a population.

4.1. Limitations

Endothelial function was measured 4 to 6 weeks after the acute event when all patients were treated with similar secondary preventive medications that included statins and frequently ACE inhibitors, which might have had a favorable effect on endothelial function [33]. However, this accounts for both study groups, and there was no significant

Table 1
Demographics and risk factors of 68 patients classified as high-risk versus low-to-intermediate-risk.

	High-risk group (n = 11)	Low-to-intermediate-risk group (n = 57)	P
Age	59.3 ± 11.8 (41.2–78.8)	57.3 ± 9.3 (38.3–76.9)	0.54
Men, n (%)	8 (72.7)	45 (78.9)	0.70
Systolic blood pressure ^a	125.1 ± 13.2 (103–144)	132.8 ± 15.9 (104–172)	0.15
Diastolic blood pressure ^a	75.5 ± 8.9 (60–92)	80.5 ± 11.7 (59–108)	0.20
Hypertension, n (%)	4 (36.4)	16 (28.1)	0.72
Hyperlipidaemia, n (%)	3 (27.3)	14 (24.6)	1.00
Diabetes, n (%)	2 (18.2)	7 (12.3)	0.63
Smoking, n (%)	6 (54.5)	21 (36.8)	0.32
Body mass index ^b	27.3 ± 2.9 (22.2–33.1)	28.6 ± 4.7 (21.0–51.0)	0.39
10-year Framingham risk ^a	14.2 ± 6.8 (1.4–20.8)	10.0 ± 5.4 (1.8–23.0)	0.03

Data are mean ± standard deviation (range) unless otherwise indicated.

% indicate percentage within column.

^a Missing: 1.

^b Missing: ≥2.

Table 2
Laboratory parameters and medication of 68 patients classified as high-risk versus low-to-intermediate-risk.

	High-risk group (n = 11)	Low-to-intermediate-risk group (n = 57)	P
Laboratory parameters			
Glucose (mmol/L) ^a	5.65 ± 1.79 (4.38–10.74)	5.65 ± 1.67 (4.16–14.79)	0.99
HbA1C, n (%) ^b	6.06 ± 1.04 (5.16–9.08)	6.00 ± 0.84 (4.89–9.39)	0.86
Total cholesterol (mmol/L)	3.45 ± 0.85 (2.35–4.66)	3.41 ± 0.77 (2.28–5.68)	0.86
HDL cholesterol (mmol/L)	0.97 ± 0.26 (0.66–1.51)	1.09 ± 0.24 (0.66–1.62)	0.14
LDL cholesterol (mmol/L)	1.93 ± 0.72 (0.92–3.10)	1.68 ± 0.57 (0.68–3.50)	0.21
Triglycerides (mmol/L)	1.24 ± 0.49 (0.67–2.26)	1.42 ± 0.78 (0.60–4.56)	0.47
Apo A1 (g/L) ^a	1.24 ± 0.15 (0.99–1.53)	1.21 ± 0.25 (0.60–1.64)	0.68
Apo B 100 (g/L) ^a	0.78 ± 0.24 (0.52–1.17)	0.65 ± 0.20 (0.35–1.29)	0.10
Creatinine (μmol/L)	79.46 ± 19.67 (49.80–108.10)	81.31 ± 17.72 (48.60–142.10)	0.76
Fibrinogen (g/L)	4.84 ± 0.87 (3.70–6.20)	3.71 ± 0.75 (2.30–6.40)	<0.001
NT-proBNP (pmol/L)	93.83 ± 106.54 (16.66–340.2)	44.29 ± 48.44 (1.62–281.70)	0.02
hs CRP (mg/L)	6.82 ± 2.56 (3.99–13.10)	2.84 ± 3.70 (0.15–20.30)	0.001
Lp-PLA ₂ (ng/mL)	265.00 ± 29.24 (239.0–331.0)	207.21 ± 40.27 (137.0–315.0)	<0.001
Resistin (ng/mL)	13.06 ± 6.82 (6.60–25.70)	11.01 ± 6.01 (4.00–34.30)	0.30
RH-PAT	1.68 ± 0.22 (1.45–2.11)	1.95 ± 0.63 (1.10–3.63)	0.17
Medication			
Beta blockers, n (%) ^b	8 (80.0%)	47 (85.5%)	0.65
Calcium ch. blockers, n (%) ^b	2 (20.0%)	10 (18.2%)	1.00
ACE-inhibitors, n (%) ^b	6 (60.0%)	27 (49.1%)	0.73
AT II antagonists, n (%) ^b	1 (10.0%)	8 (14.5%)	1.00
Statins, n (%) ^b	10 (100.0%)	51 (92.7%)	1.00
Acetylsalicylic acid, n (%) ^b	9 (90.0%)	53 (96.4%)	0.40
Clopidogrel, n (%) ^b	8 (80%)	52 (94.5%)	0.17
Oral anticoagulation, n (%) ^b	1 (10%)	2 (3.6%)	0.40

Data are mean ± standard deviation (range) unless otherwise indicated.

ACE = angiotensin-converting enzyme. Apo 1 = Apolipoprotein 1. Apo B 100 = Apolipoprotein B 100. AT II = angiotensin receptor antagonist. Ch. = channel. HDL = high-density lipoprotein. LDL = low-density lipoprotein.

^a Missing: 1.

^b Missing: >2.

between-group difference in medical treatment. The present substudy of the RESPONSE trial is limited by its relatively small sample size, and its findings were meant to be hypothesis generating only. Nevertheless, there is an absence of any other large studies on the relation between

elevated inflammatory biomarkers and endothelial function in patients with a recent STEMI.

5. Conclusions

In this population of patients with recent STEMI and PPCI, we observed between patients with high hs-CRP and Lp-PLA levels and all other patients no more than numerical dissimilarities in endothelial function that did not reach a statistical significance. Nevertheless, further research in larger patient populations may be warranted.

Acknowledgment

The authors thank Mrs. Liefke C. van der Heijden, MD, for her assistance with preparing the figure.

References

- [1] Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. *Am J Cardiol* 2008;102:1K–34K.
- [2] Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 2002;347:1557–65.
- [3] Eapen DJ, Manocha P, Patel RS, Hammadah M, Veledar E, Wassel C, et al. Aggregate Risk score based on markers of inflammation, cell stress and coagulation is an independent predictor of adverse cardiovascular events. *J Am Coll Cardiol* 2013;62:329–37.
- [4] Thompson A, Gao P, Orfei L, Watson S, di Angelantonio E, Kaptoge S, et al. The Lp-PLA₂ Studies Collaboration: Lipoprotein-associated phospholipase A₂ and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. *Lancet* 2010;375:1536–44.
- [5] Koenig W, Khuseynova N, Löwel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. *Circulation* 2004;110:1903–8.
- [6] O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. Lipoprotein-associated phospholipase A₂ and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22




Fig. 1. Endothelial function as measured by RH-PAT in risk stratification groups. The mean RH-PAT index in the low-intermediate group was 1.95 ± 0.63 and in the high-risk group 1.68 ± 0.22 (*p* = 0.17).

- (PRavastatin or atorVastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction) Trial. *Circulation* 2006;113:1745–52.
- [7] Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A₂, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. *Arch Intern Med* 2005;165:2479–84.
 - [8] Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. *Stroke* 2009;40:376–81.
 - [9] Wang X, Guo F, Li G, Cao Y, Fu H. Prognostic role of brachial reactivity in patients with ST myocardial infarction after percutaneous coronary intervention. *Coron Artery Dis* 2009;20:467–72.
 - [10] Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. *Am J Cardiol* 1997;80:11–I–6–I.
 - [11] Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. *Arterioscler Thromb Vasc Biol* 2003;23:169–75.
 - [12] Jørstad HT, von Birgelen C, Alings AM, Liem A, Dantzig JM, Jaarsma W, et al. Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. *Heart* 2013;99:1421–30.
 - [13] Blum A, Schneider DJ, Burton E, Sobel BE, Dauerman HL. Endothelial dysfunction and inflammation after percutaneous coronary intervention. *Am J Cardiol* 2004;94:1420–3.
 - [14] Solheim S, Grogaard HK, Hoffmann P, Arnesen H, Seljeflot I. Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris. *Scand J Clin Lab Invest* 2008;68:556–62.
 - [15] Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients. *Int J Cardiol* 2004;94:111–7.
 - [16] Kandhai-Ragunath JJ, Jørstad HT, de Man FH, Peters RJ, von Birgelen C. Approaches for non-invasive assessment of endothelial function: focus on peripheral arterial tonometry. *Neth Heart J* 2013;21:214–8.
 - [17] Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from centers for disease control and prevention and the American Heart Association. *Circulation* 2003;107:499–511.
 - [18] Kandhai-Ragunath JJ, Jørstad HT, de Wagenaar B, de Man FH, Stoel GM, van Es J, et al. Assessment of the relation between initial culprit vessel patency in acute ST-elevation myocardial infarction and endothelial function. *EuroIntervention* 2014;10:784–91.
 - [19] Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. *J Appl Physiol* 2006;101:545–8.
 - [20] Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. *Circulation* 2008;117:2467–74.
 - [21] Bonetti PO, Pumper GM, Higano ST, Holmes Jr DR, Kuvin JT, Lerman A. Non-invasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. *J Am Coll Cardiol* 2004;44:2137–41.
 - [22] Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). *BMJ* 2006;333:1091–4.
 - [23] Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation* 2000;101:1899–906.
 - [24] Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. *Eur Heart J* 2010;31:1142–8.
 - [25] Kuvin JT, Mammen A, Money P, Alsheikh-Ali AA, Karas RH. Assessment of peripheral vascular endothelial function in the ambulatory setting. *Vasc Med* 2007;12:13–6.
 - [26] Toggweiler S, Schoenenberger A, Urbanek N, Erne P. The prevalence of endothelial dysfunction in patients with and without coronary artery disease. *Clin Cardiol* 2010;33:746–52.
 - [27] Warnholtz A, Ostad MA, Heitzer T, Goldmann BU, Nowak G, Munzel T. Effects of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease. *Am J Cardiol* 2005;95:20–3.
 - [28] Azar R, McKay R, Kierman F, Seecharan B, Feng YJ, Fram DB, et al. Coronary angioplasty induces a systemic inflammatory response. *Am J Cardiol* 1997;80:1476–8.
 - [29] Heffernan KS, Karas RH, Patvardhan EA, Jafri H, Kuvin JT. Peripheral arterial tonometry for risk stratification in men with coronary artery disease. *Clin Cardiol* 2010;33:94–8.
 - [30] Della Rocca DG, Pepine CJ. Endothelium as a predictor of adverse outcomes. *Clin Cardiol* 2010;33:730–2.